<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font7" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font8" size="10" family="Symbol" color="#ffffff"/>
	<fontspec id="font9" size="10" family="GillSans" color="#ffffff"/>
	<fontspec id="font10" size="10" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font11" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font12" size="10" family="GillSans,Italic" color="#000000"/>
<text top="41" left="55" width="182" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Cell Communication and Signaling 2005, 3 :10<i>Cell Communication and Signaling</i></text>
<text top="41" left="383" width="171" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.biosignaling.com/content/3/1/10</text>
<text top="756" left="503" width="51" height="10" font="font1" id="p1_t3" reading_order_no="47" segment_no="7" tag_type="text">Page 5 of 10<b>3</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="48" segment_no="8" tag_type="text">(page number not for citation purposes)</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="13" segment_no="4" tag_type="text">cAMPS. Cell pretreatment in serum-free DMEM contain-</text>
<text top="543" left="55" width="241" height="13" font="font4" id="p1_t6" reading_order_no="14" segment_no="4" tag_type="text">ing 100 nM of H-89 or 10 µ M of Rp-cAMPS did not signif-</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="15" segment_no="4" tag_type="text">icantly alter levels of pERK after stimulation with<i>(page number not for citation purposes)</i></text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="16" segment_no="4" tag_type="text">isoproterenol when compared to cells preincubated in the</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="17" segment_no="4" tag_type="text">absence of PKA inhibitors (Figure 5). Increases in pERK</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="18" segment_no="4" tag_type="text">when compared to basal were still detected following H-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="19" segment_no="4" tag_type="text">89 or Rp-cAMPS pretreatment with peak levels generated</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="20" segment_no="4" tag_type="text">at 5 min. Semi-quantitave analysis of the immunoblots</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="21" segment_no="4" tag_type="text">revealed a 1.9 ± 0.4 and 2.6 ± 0.7 fold increase in pERK</text>
<text top="639" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="22" segment_no="4" tag_type="text">levels over basal after H-89 ( n = 4) or Rp-cAMPS ( n = 3)<a href="">5). Incr</a>eases in pERK</text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="23" segment_no="4" tag_type="text">pretreatment, respectively, which are not significantly dif-</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="24" segment_no="4" tag_type="text">ferent than the fold increase for pERK observed without</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="25" segment_no="4" tag_type="text">inhibitor pretreatment (2.6 ± 0.9; n = 4). Results of these</text>
<text top="684" left="55" width="241" height="13" font="font4" id="p1_t18" reading_order_no="26" segment_no="4" tag_type="text">experiments demonstrate that β -AR stimulated MAPK</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="27" segment_no="4" tag_type="text">activation in UROtsa cells is not dependent upon genera-</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="28" segment_no="4" tag_type="text">tion of cAMP production and subsequent activation of<i>n </i></text>
<text top="721" left="55" width="20" height="9" font="font4" id="p1_t21" reading_order_no="29" segment_no="4" tag_type="text">PKA.</text>
<text top="533" left="313" width="237" height="9" font="font7" id="p1_t22" reading_order_no="30" segment_no="5" tag_type="title">PKA-Independent Production of Inflammatory Mediators<i>n </i></text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t23" reading_order_no="31" segment_no="6" tag_type="text">Although previous results revealed that MAPK activation</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t24" reading_order_no="32" segment_no="6" tag_type="text">is not dependent upon PKA activation, we were interested</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t25" reading_order_no="33" segment_no="6" tag_type="text">in whether or not production of inflammatory mediators</text>
<text top="578" left="313" width="241" height="13" font="font4" id="p1_t26" reading_order_no="34" segment_no="6" tag_type="text">initiated by β -AR activation also occurred under PKA-</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t27" reading_order_no="35" segment_no="6" tag_type="text">independent mechanisms. Pretreatment of UROtsa cells<i>n </i></text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t28" reading_order_no="36" segment_no="6" tag_type="text">with selective concentrations of H-89 (100 nM) or Rp-</text>
<text top="613" left="313" width="241" height="13" font="font4" id="p1_t29" reading_order_no="37" segment_no="6" tag_type="text">cAMPS (10 µ M), again did not affect production of COX-</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t30" reading_order_no="38" segment_no="6" tag_type="text">2 or iNOS 2 hrs after addition of isoproterenol, when</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t31" reading_order_no="39" segment_no="6" tag_type="text">compared to cells pretreated in the absence of inhibitor</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t32" reading_order_no="40" segment_no="6" tag_type="text">(Figure 6). In these experiments, levels of COX-2 gener-</text>
<text top="660" left="313" width="241" height="13" font="font4" id="p1_t33" reading_order_no="41" segment_no="6" tag_type="text">ated by β -AR activation in the presence of H-89 ( n = 3) or</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t34" reading_order_no="42" segment_no="6" tag_type="text">Rp-cAMPS ( n = 3) were increased 3.0 ± 0.4 and 2.5 ± 0.7</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t35" reading_order_no="43" segment_no="6" tag_type="text">fold over basal, respectively. This level of COX-2<i><b>PKA-Independent Production of Inflammatory Mediators</b></i></text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t36" reading_order_no="44" segment_no="6" tag_type="text">expression in response to isoproterenol was not signifi-</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t37" reading_order_no="45" segment_no="6" tag_type="text">cantly different from cells pretreated in the absence of</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t38" reading_order_no="46" segment_no="6" tag_type="text">inhibitor (1.9 ± 0.5 fold over basal; n = 5). Likewise, levels</text>
<text top="357" left="55" width="362" height="13" font="font8" id="p1_t39" reading_order_no="2" segment_no="2" tag_type="title">β -AR stimulation activates the MAPK pathway after treatment with selective PKA inhibitors</text>
<text top="359" left="55" width="37" height="9" font="font10" id="p1_t40" reading_order_no="3" segment_no="2" tag_type="title">Figure 5</text>
<text top="367" left="55" width="499" height="13" font="font5" id="p1_t41" reading_order_no="4" segment_no="3" tag_type="text">β -AR stimulation activates the MAPK pathway after treatment with selective PKA inhibitors . After a 30 min pre-</text>
<text top="378" left="55" width="497" height="13" font="font11" id="p1_t42" reading_order_no="5" segment_no="3" tag_type="text">incubation with 100 nM of the PKA inhibitors H-89 ( panel A ) or 10 µ M of Rp-cAMPS ( panel B ), UROtsa cells were stimulated</text>
<text top="391" left="55" width="499" height="9" font="font11" id="p1_t43" reading_order_no="6" segment_no="3" tag_type="text">with 100 nM isoproterenol for the indicated times and immunoblotted with anti-pERK or anti-ERK2. Peak levels of pERK were</text>
<text top="402" left="55" width="493" height="9" font="font11" id="p1_t44" reading_order_no="7" segment_no="3" tag_type="text">observed within 5 min after the addition of isoproterenol with no changes in the total cell lysate levels of ERK2. Semi-quanti-</text>
<text top="413" left="55" width="483" height="9" font="font11" id="p1_t45" reading_order_no="8" segment_no="3" tag_type="text">tave analysis of the immunoblots revealed a time-dependent increase in ERK phosphorylation ( panel C ). Five minutes after</text>
<text top="424" left="55" width="499" height="9" font="font11" id="p1_t46" reading_order_no="9" segment_no="3" tag_type="text">treatment, isoproterenol significantly induced a 1.9 ± 0.4 and 2.6 ± 0.7 fold increase in pERK levels over basal after H-89 or Rp-</text>
<text top="434" left="55" width="498" height="9" font="font11" id="p1_t47" reading_order_no="10" segment_no="3" tag_type="text">cAMPS pretreatment, respectively. These peak values are not significantly different than the fold increase over basal for pERK</text>
<text top="445" left="55" width="499" height="9" font="font11" id="p1_t48" reading_order_no="11" segment_no="3" tag_type="text">measured in the absence of PKA inhibitor (2.6 ± 0.9). Values are presented as the mean ± S.E. and the autoradiographs are rep-</text>
<text top="456" left="55" width="291" height="9" font="font11" id="p1_t49" reading_order_no="12" segment_no="3" tag_type="text">resentative immunoblots of n = 3–4 independent UROtsa cell treatments.<a href="">(Figure 6)</a>. In these experiments, levels of COX-2 gener-</text>
</page>
</pdf2xml>
